Suppr超能文献

颈动脉粥样硬化的血清标志物研究综述。

Review of serum biomarkers in carotid atherosclerosis.

机构信息

Hospital de Mataró, Consorci Sanitari del Maresme, Barcelona, Spain; Hospital Clínic de Barcelona, Universitat de Barcelona, Barcelona, Spain.

IQS School of Engineering, Universitat Ramon Llull, Barcelona, Spain.

出版信息

J Vasc Surg. 2020 Jan;71(1):329-341. doi: 10.1016/j.jvs.2019.04.488. Epub 2019 Jul 18.

Abstract

BACKGROUND

Carotid artery atherosclerotic stenosis is a preventable major cause of stroke, but there is still a need for definition of high-risk plaque in asymptomatic patients who might benefit from interventional therapies. Several image markers are recommended to characterize unstable plaques. The measurement of serum biomarkers is a promising method to assist in decision making, but the lack of robust evidence in the carotid environment burdens their potential as a standard of care. The goal of this review was to offer an updated state-of-the-art study of available serum biomarkers with clinical implications, with focus on those that may predict carotid symptom development.

METHODS

The Cochrane Library and MEDLINE databases were searched (all until September 2018) for studies on carotid plaque and serum biomarkers of atherosclerosis. Nonhuman, basic science, and histology studies were excluded, focusing on clinical studies. Selected abstracts were screened to include the most relevant articles on atherosclerotic plaque presence, progression, instability or symptom development.

RESULTS

Some well-established biomarkers for coronary disease are not relevant to carotid atherosclerosis and other inflammatory biomarkers, lipids, interleukins, homocysteine, and adipokines may be useful in quantifying carotid disease-related risk. Some serum biomarkers combined with image features may assist vascular specialists in selecting patients at high risk for stroke and in need of intervention.

CONCLUSIONS

Prospective studies applying a combination of biomarkers are essential to prove clinical usefulness.

摘要

背景

颈动脉粥样硬化性狭窄是可预防的中风主要原因,但仍需要为无症状患者定义高危斑块,以便从介入治疗中获益。有几种影像学标志物被推荐用于表征不稳定斑块。血清生物标志物的测量是一种很有前途的辅助决策方法,但在颈动脉环境中缺乏强有力的证据限制了它们作为护理标准的潜力。本综述的目的是提供最新的、具有临床意义的颈动脉斑块和动脉粥样硬化血清生物标志物的研究现状,重点关注那些可能预测颈动脉症状发展的标志物。

方法

对 Cochrane 图书馆和 MEDLINE 数据库(均截至 2018 年 9 月)进行了检索,以获取有关颈动脉斑块和动脉粥样硬化血清生物标志物的研究。排除了非人类、基础科学和组织学研究,重点关注临床研究。筛选了选定的摘要,以纳入有关动脉粥样硬化斑块存在、进展、不稳定性或症状发展的最相关文章。

结果

一些已确立的用于冠心病的生物标志物与颈动脉粥样硬化无关,其他炎症生物标志物、脂质、白细胞介素、同型半胱氨酸和脂肪因子可能有助于量化与颈动脉疾病相关的风险。一些血清生物标志物与影像学特征相结合,可能有助于血管专家选择发生中风风险高且需要干预的患者。

结论

应用联合生物标志物的前瞻性研究对于证明其临床实用性至关重要。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验